HuGE Literature Finder
Records
1
-
30
| Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ breast cancer 2021 Mar 7 (1): 34. DeCensi Andrea, Johansson Harriet, Helland Thomas, Puntoni Matteo, Macis Debora, Aristarco Valentina, Caviglia Silvia, Webber Tania Buttiron, Briata Irene Maria, D'Amico Mauro, Serrano Davide, Guerrieri-Gonzaga Aliana, Bifulco Ersilia, Hustad Steinar, Søiland Håvard, Boni Luca, Bonanni Bernardo, Mellgren Gunn |
| The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China. Malaria journal 2021 Mar 20 (1): 160. Huang Herong, Dong Ying, Xu Yanchun, Deng Yan, Zhang Canglin, Liu Shuping, Chen Mengni, Liu Y |
| Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. Scientific reports 2021 Jan 11 (1): 415. Sanchez-Spitman A B, Swen J J, Dezentjé V O, Moes D J A R, Gelderblom H, Guchelaar H |
| Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions. Pharmacogenomics and personalized medicine 2021 14 279-286. Jeiziner Chiara, Stäuble Céline K, Lampert Markus L, Hersberger Kurt E, Meyer Zu Schwabedissen Henriette |
| Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant). Medicine 2020 Feb 99 (8): e19083. Chan Carmen Wing Han, Miaskowski Christine, McCarthy Alexandra, Waye Mary Miu Yee, Yeo Winnie, So Winnie Kwok Wai, Choi Kai Chow, Tsui Stephen Kwok Wing, Chan Judy Yuet |
| CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. Malaria journal 2018 Feb 17 (1): 57. Brasil Larissa W, Rodrigues-Soares Fernanda, Santoro Ana B, Almeida Anne C G, Kühn Andrea, Ramasawmy Rajendranath, Lacerda Marcus V G, Monteiro Wuelton M, Suarez-Kurtz Guilher |
| Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. The pharmacogenomics journal 2018 04 18 (2): 201-208. Hwang G S, Bhat R, Crutchley R D, Trivedi M |
| Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. Advances in pharmacology (San Diego, Calif.) 2018 83 65-91. Cronin-Fenton Deirdre P, Damkier P |
| CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast cancer research and treatment 2017 Nov 166 (1): 277-287. Hertz D L, Kidwell K M, Hilsenbeck S G, Oesterreich S, Osborne C K, Philips S, Chenault C, Hartmaier R J, Skaar T C, Sikora M J, Rae J |
| CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. Scientific reports 2017 Aug 7 (1): 7727. Damkier Per, Kjærsgaard Anders, Barker Kimberly A, Cronin-Fenton Deidre, Crawford Anatasha, Hellberg Ylva, Janssen Emilius A M, Langefeld Carl, Ahern Thomas P, Lash Timothy |
| The effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancer. Pakistan journal of pharmaceutical sciences 2017 May 30 (3(Special)): 1095-1098. Zeng Yi, Huang Kai, Huang Weiw |
| The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis. OncoTargets and therapy 2017 10 5429-5437. Lu Junjun, Li He, Guo Peng, Shen Rui, Luo Yingbin, Ge Qiao, Shi Wenfei, Li Yan, Zhu Weika |
| CYP2D6 gene polymorphisms in Brazilian patients with breast cancer treated with adjuvant tamoxifen and its association with disease recurrence. Biomedical reports 2016 Nov 5 (5): 574-578. De Ameida Melo Mariella, De Vasconcelos-Valença Rodrigo José, Neto Fidelis Manes, Borges Rafael Soares, Costa-Silva Danylo Rafhael, Da Conceição Barros-Oliveira Maria, Borges Umbelina Soares, Alencar Airlane Pereira, Silva Vladimir Costa, Da Silva Benedito Borg |
| Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Feb . Fox Peter, Balleine Rosemary, Lee Clara, Gao Bo, Balakrishnar Bavanthi, Menzies Alexander M, Yeap Shang Heng, Ali Sayed Sahanawaz, Gebski Val, Provan Pamela J, Coulter Sally, Liddle Christopher, Hui Rina, Kefford Richard F, Lynch Jodi, Wong Mark, Wilcken Nicholas, Gurney Howa |
| CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer? Breast (Edinburgh, Scotland) 2015 Aug 24 (4): 481-6. Abreu M H, Gomes M, Menezes F, Afonso N, Abreu P H, Medeiros R, Pereira D, Lopes |
| Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen. Pharmacogenetics and genomics 2015 Apr 25 (4): 157-63. Safgren Stephanie L, Suman Vera J, Kosel Matthew L, Gilbert Judith A, Buhrow Sarah A, Black John L, Northfelt Donald W, Modak Anil S, Rosen David, Ingle James N, Ames Matthew M, Reid Joel M, Goetz Matthew |
| CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients. Asian Pacific journal of cancer prevention : APJCP 2015 16 (15): 6783-7. Yazdi Mohammad Forat, Rafieian Shiva, Gholi-Nataj Mohsen, Sheikhha Mohammad Hasan, Nazari Tahereh, Neamatzadeh Hosse |
| Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis. Pharmacogenomics 2014 Jan 15 (1): 49-60. Jung Jin-A, Lim Hyeong-Se |
| CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. SpringerPlus 2013 Dec 2 (1): 52. Love Richard R, Desta Zuerenesay, Flockhart David, Skaar Todd, Ogburn Evan T, Ramamoorthy Anuradha, Uy Gemma B, Laudico Adriano V, Van Dinh Nguyen, Quang Le Hong, Van To Ta, Young Gregory S, Hade Erinn, Jarjoura Dav |
| CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast cancer research and treatment 2013 May 139 (1): 95-105. Teft Wendy A, Gong Inna Y, Dingle Brian, Potvin Kylea, Younus Jawaid, Vandenberg Theodore A, Brackstone Muriel, Perera Francisco E, Choi Yun-Hee, Zou Guangyong, Legan Robin M, Tirona Rommel G, Kim Richard |
| CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics 2013 Apr 14 (6): 613-22. Margolin Sara, Lindh Jonatan D, Thorén Linda, Xie Hanjing, Koukel Larissa, Dahl Marja-Liisa, Eliasson Er |
| The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. Cancer chemotherapy and pharmacology 2013 Mar 71 (3): 593-601. Opdam F L, Dezentje V O, den Hartigh J, Modak A S, Vree R, Batman E, Smorenburg C H, Nortier J W R, Gelderblom H, Guchelaar H |
| CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jan 19 (2): 500-7. Goetz Matthew P, Suman Vera J, Hoskin Tanya L, Gnant Michael, Filipits Martin, Safgren Stephanie L, Kuffel Mary, Jakesz Raimund, Rudas Margaretha, Greil Richard, Dietze Otto, Lang Alois, Offner Felix, Reynolds Carol A, Weinshilboum Richard M, Ames Matthew M, Ingle James |
| Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmacogenomics and personalized medicine 2013 6 37-48. Chamnanphon Montri, Pechatanan Khunthong, Sirachainan Ekapob, Trachu Narumol, Chantratita Wasun, Pasomsub Ekawat, Noonpakdee Wilai, Sensorn Insee, Sukasem Chonlaph |
| Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmacogenomics and personalized medicine 2013 6 93-8. Sensorn Insee, Sirachainan Ekaphop, Chamnanphon Montri, Pasomsub Ekawat, Trachu Narumol, Supavilai Porntip, Sukasem Chonlaphat, Pinthong Daraw |
| CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PloS one 2013 8 (10): e76648. Lum Danny W K, Perel Pablo, Hingorani Aroon D, Holmes Michael |
| Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients. PloS one 2013 8 (7): e70183. Fernández-Santander Ana, Gaibar María, Novillo Apolonia, Romero-Lorca Alicia, Rubio Margarita, Chicharro Luis Miguel, Tejerina Armando, Bandrés Fernan |
| Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. International journal of molecular epidemiology and genetics 2013 4 (1): 35-48. Brooks Jennifer D, Teraoka Sharon N, Malone Kathleen E, Haile Robert W, Bernstein Leslie, Lynch Charles F, Mellemkjær Lene, Duggan David J, Reiner Anne S, Concannon Patrick, Schiermeyer Katherine, Lewinger Juan Pablo, , Bernstein Jonine L, Figueiredo Jane |
| Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen. Clinical laboratory 2012 58 (11-12): 11-12. Rolla R, Vidali M, Meola S, Pollarolo P, Fanello MR, Nicolotti C, Saggia C, Forti L, Agostino FD, Rossi V, Borra G, Stratica F, Alabiso O, Bellomo G |
| CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmacogenomics and personalized medicine 2012 5 149-53. Sirachainan Ekaphop, Jaruhathai Sureerat, Trachu Narumol, Panvichian Ravat, Sirisinha Thitiya, Ativitavas Touch, Ratanatharathorn Vorachai, Chamnanphon Montri, Sukasem Chonlaph |
- Page last reviewed:Oct 1, 2021
- Page last updated:May 11, 2022
- Content source: